#ESMO25: BioNTech stops further work on cancer vaccine in advanced melanomanews2025-10-18T14:11:16+00:00October 18th, 2025|Endpoints News|
John Carroll’s Q3 analysis; Q&A with a Nobel Prize winner; Excellergy’s allergy plan; and morenews2025-10-18T10:00:50+00:00October 18th, 2025|Endpoints News|
#ESMO25: Celcuity details Phase 3 breast cancer win as it works on FDA submissionnews2025-10-18T08:30:30+00:00October 18th, 2025|Endpoints News|
#ESMO25: Roche’s SERD is the first shown to work in non-mutant breast cancer patientsnews2025-10-18T05:00:27+00:00October 18th, 2025|Endpoints News|
#ESMO25: Grail’s cancer test better at spotting real cases as FDA filing nearsnews2025-10-17T22:05:05+00:00October 17th, 2025|Endpoints News|
#AAO25: Roche’s eye drug yields one hit, one miss in pivotal trialsnews2025-10-17T20:20:59+00:00October 17th, 2025|Endpoints News|
Meet the first nine recipients of the FDA’s new vouchernews2025-10-17T19:31:44+00:00October 17th, 2025|Endpoints News|
Robotic pill maker Rani teams up with Chugai in deal worth up to $1.08Bnews2025-10-17T15:21:42+00:00October 17th, 2025|Endpoints News|
CHMP rejects Sanofi’s Rezurock over clinical data issues, but recommends Wayrilznews2025-10-17T14:44:13+00:00October 17th, 2025|Endpoints News|
Kezar seeks strategic alternatives after FDA setback; Taysha, Astellas’ Rett syndrome agreement expiresnews2025-10-17T14:07:20+00:00October 17th, 2025|Endpoints News|
